Forest Labs and Adamas Pharma sign agreement to develop dementia treatment

December 14, 2012

Dec 14, 2012 -- Forest Laboratories, Inc., a pharmaceutical company, and Adamas Pharmaceuticals, Inc. have entered into an agreement for the development and commercialization of a fixed dosed combination, or FDC, of Namenda XR and donepezil HCI as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer's type in the US.

Under the agreement, Forest and Adamas will collaborate on the development of the FDC and Forest will have exclusive US commercialization rights. Forest is responsible for all development and commercialization activities.

Namenda XR is Forest's FDA approved, once daily formulation of its Alzheimer's therapy Namenda. Based on a development plan agreed to by Adamas and the FDA, the FDC is expected to launch in 2015 following FDA approval. The product will be covered by multiple Adamas patents that extend to 2029. Forest sells Namenda in the US under a 2000 license from Merz & Co. GmbH & Co.

"We are pleased to enter into this partnership with Adamas, which will enable us to enhance our life cycle program for Namenda," said Howard Solomon, Chairman, CEO and President of Forest. "Adamas has made impressive progress with its combination extended release memantine and donepezil program. Forest is the ideal company to complete the development of this product and commercialize it in the US, in light of our track record in the field of Alzheimer's disease with Namenda.

Gregory Went, CEO of Adamas Pharmaceuticals said: "We are pleased to partner with Forest, the market leader in Alzheimer's products, to bring our fixed dose combination of extended release memantine and donepezil - the first such combination therapy for Alzheimer's disease - to the US market.

"This collaboration will accelerate this innovative product's development towards a 2014 US NDA filing, and allow Adamas to focus our attention on the ex-US market for the product and to continue the ongoing development of Nurelin, our late-stage product candidate for the treatment of CNS disorders, including Parkinson's disease."